Related Experiment Video
Updated: Aug 26, 2025
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA-641 Inhibits Endometrial Cancer Progression via Targeting AP1G1
Yanfen Dong1, He Yang2, Handan Hua2
1Department of Laboratory, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou 213003, China.
Abstract:
MicroRNA-641 (miR-641) was significantly decreased in various cancers, but its roles in endometrial cancer (EC) remain unclear. We explored the influences of miR-641 on the EC cells. In our study, the miR-641 expression was reduced in EC cells. Overexpression of miR-641 inhibited viability and proliferation of HEC-1A and HECCL-1 cells by CCK-8 and colony formation assays. Additionally, flow cytometry revealed that overexpression of miR-641 could remarkably promote apoptosis and arrest the cell cycle at the G1 phase of HEC-1A and HECCL-1 cells. Besides, forced expression of miR-641 suppressed the migration and invasion of HEC-1A and HECCL-1 cells as evidenced by wound healing and transwell assay. Moreover, AP1G1 was confirmed as a target gene of miR-641 by StarBase prediction and DLR assay and their expressions were negatively correlated. Overexpression of AP1G1 neutralized the roles of miR-641 mimic on the viability, proliferation, apoptosis, and migration of HEC-1A and HECCL-1 cells. Our findings illustrated that miR-641 was reduced in the EC cells and AP1G1 antagonized the miR-641 mimic-induced inhibition of the EC progression in vitro. Therefore, miR-641 may emerge as an effective molecule for EC treatment.
Insights
MicroRNA-641 (miR-641) levels are reduced in endometrial cancer (EC). Restoring miR-641 inhibits EC cell growth, promotes apoptosis, and reduces migration, suggesting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA-641 (miR-641) is downregulated in various cancers, but its function in endometrial cancer (EC) is not well understood.
- Endometrial cancer (EC) is a significant gynecological malignancy with a need for novel therapeutic targets.
Purpose of the Study:
- To investigate the role of miR-641 in endometrial cancer (EC) cell lines.
- To identify potential molecular mechanisms underlying miR-641's function in EC progression.
Main Methods:
- Quantitative real-time PCR to assess miR-641 expression.
- Cell Counting Kit-8 (CCK-8) and colony formation assays to evaluate cell viability and proliferation.
- Flow cytometry for apoptosis and cell cycle analysis.
- Wound healing and Transwell assays for migration and invasion.
- Bioinformatic prediction (StarBase) and Dual-Luciferase Reporter (DLR) assay to validate miR-641 targets.
- Rescue experiments involving AP1G1 overexpression.
Main Results:
- miR-641 expression was significantly decreased in EC cell lines (HEC-1A and HECCL-1).
- Overexpression of miR-641 inhibited EC cell viability, proliferation, migration, and invasion.
- miR-641 restoration induced apoptosis and G1 phase cell cycle arrest.
- AP1G1 was identified as a direct target gene of miR-641, with inverse expression correlation.
- Overexpression of AP1G1 counteracted the inhibitory effects of miR-641 on EC cell progression.
Conclusions:
- miR-641 functions as a tumor suppressor in endometrial cancer (EC) by inhibiting cell proliferation, migration, and invasion.
- AP1G1 acts as an oncogene in EC and mediates resistance to miR-641's tumor-suppressive effects.
- miR-641 represents a potential therapeutic target for endometrial cancer (EC) treatment.
Related Concept Videos
01:22MicroRNAs
02:15Experimental RNAi